CITIUS ONCOLOGY INC
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
CTOR$0.56+2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
| Exhibit Number | Description of Document | Registrant’s Form | Dated | Exhibit Number | Filed Herewith |
|---|---|---|---|---|---|
| 2.1* | Agreement and Plan of Merger and Reorganization, dated as of October 23, 2023, by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc. | 8-K | 10/24/2023 | 2.1 | |
| 3.1 | Certificate of Incorporation of Citius Oncology, Inc. | 8-K | 08/16/2024 | 3.1 | |
| 3.2 | Bylaws of Citius Oncology, Inc. | 8-K | 08/16/2024 | 3.2 | |
| 4.1 | Specimen Common Stock Certificate of Citius Oncology, Inc. | S-4 | 07/11/2024 | 4.5 | |
| 4.2 | Description of Common Stock. | X | |||
| 10.1 | Amended and Restated Registration Rights Agreement, dated as of August 12, 2024 by and between Citius Oncology, Inc. and the signatories thereto. | 8-K | 08/16/2024 | 10.1 | |
| 10.2 | Amended and Restated Shared Services Agreement, dated as of August 12, 2024, by and among Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. | 8-K | 08/16/2024 | 10.2 | |
| 10.3† | 2023 Omnibus Stock Incentive Plan. | X | |||
| 10.4† | 2024 Omnibus Stock Incentive Plan. | 8-K | 8/5/2024 | 10.5 | |
| 10.5* | Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy’s Laboratories S.A. and Citius Pharmaceuticals, Inc. | S-4 | 11/13/2023 | 10.15 | |
| 10.6* | Amended and Restated License, Development and Commercialization Agreement, dated as of February 26, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | S-4 | 11/13/2023 | 10.16 | |
| 10.7* | Amendment No. 1 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 9, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | S-4 | 11/13/2023 | 10.17 | |
| 10.8* | Amendment No. 2 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 31, 2021, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | S-4 | 11/13/2023 | 10.18 | |
| Exhibit Number | Description of Document | Registrant’s Form | Dated | Exhibit Number | Filed Herewith |
|---|---|---|---|---|---|
| 10.9 | Side Letter Agreement, dated August 12, 2024, by and by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc. | 8-K | 08/16/2024 | 10.8 | |
| 10.10 | Promissory Note, dated July 18, 2023, issued by TenX Keane Acquisition to 10XYZ Holdings LP. | 8-K | 07/18/2023 | 10.1 | |
| 10.11 | Promissory Note, dated October 18, 2023, issued by TenX Keane Acquisition to 10XYZ Holdings LP. | 8-K | 10/18/2023 | 10.1 | |
| 10.12 | Promissory Note, dated August 16, 2024, by and between Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. | 8-K | 08/16/2024 | 10.9 | |
| 16.1 | Letter from Marcum LLP to the Securities and Exchange Commission, dated August 16, 2024. | 8-K | 08/16/2024 | 16.1 | |
| 19.1 | Insider Trading Policy. | -- | -- | -- | X |
| 31.1 | Certification of the Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a). | -- | -- | -- | X |
| 31.2 | Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a). | -- | -- | -- | X |
| 32.1 | Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002. | -- | -- | -- | X |
| EX-101.INS | INLINE XBRL INSTANCE DOCUMENT | -- | -- | -- | X |
| EX-101.SCH | INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | -- | -- | -- | X |
| EX-101.CAL | INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE | ||||
| EX-101.DEF | INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE | -- | -- | -- | X |
| EX-101.LAB | INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE | -- | -- | -- | X |
| EX-101.PRE | INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE | -- | -- | -- | X |
| 104 | Cover Page Interactive Data File, formed in Inline Extensible Business Reporting Language (iXBRL) | -- | -- | -- | X |
| * | Certain portions, schedules and exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5) or Item 601(b)(10)(iv), as applicable, of Regulation S-K. The Registrant agrees to furnish supplemental copies of all omitted portions, exhibits and schedules to the Securities and Exchange Commission upon its request. |
| † | Indicates management contract or compensatory plan. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.